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EDITORIAL REVIEW
Citrate: A major factor in the toxicity of orally administered
aluminum compounds
Initially, aluminum toxicity was recognized as a neurological
and/or skeletal disease which ocurred in epidemic proportions
in some dialysis populations, whereas it was rarely if ever seen
in others [1—4]. It soon became apparent that the source of the
aluminum responsible for this toxicity was the water used to
prepare the dialysate. Although minimizing the parenteral ex-
posure to aluminum by removing this element from the dialy-
sate has now been accomplished, toxicity continues to occur in
dialyzed as well as non-dialyzed uremic patients. Recent stud-
ies suggest that 25 to 30% of dialyzed uremic patients may have
osteomalacia secondary to aluminum toxicity [5—71. Further-
more, in as many as 80% of patients on hemodialysis aluminum
may be playing a role in metabolic bone disease [5]. The source
of the aluminum responsible for this toxicity is assumed to be
the orally administered aluminum hydroxide used as a phos-
phate binding agent.
As absorbed aluminum is primarily excreted in the urine,
uremic patients are subject to aluminum loading because of loss
of, or compromised renal function which limits or prevents
renal excretion. Because of this compromised ability to excrete
aluminum, therefore, factors which modulate the gastrointesti-
nal absorption of aluminum assume increasing importance in
renal failure patients. In this light recent evidence suggests that
uremia per se may enhance aluminum absorption from the
gastrointestinal tract. In one series of non-dialyzed uremic
patients 85% had increased tissue aluminum levels [81 even
though the majority of these patients had never received
aluminum-containing phosphate binding agents. The amount of
aluminum present in a number of tissues far exceeded what
would have resulted from simply an inability to excrete the
normal amount of dietary aluminum absorbed, suggesting that
aluminum absorption must have been increased in this patient
population. More recently Ittel et al [9] have shown that uremic
rats absorb significantly more aluminum from an oral aluminum
load than non-uremic rats.
There also may be certain uremic populations which have
even a further enhancement of aluminum absorption. Based on
bone aluminum levels and the deferoxamine provocative test, it
has been suggested that dialysis patients with diabetic renal
disease may absorb an excess amount of aluminum [101. In
addition, children with uremia appear to have an increased
incidence of aluminum loading and toxicity [11, 12]. In this
latter group it is unclear whether this results from enhanced
absorption or is a consequence of the large amount of aluminum
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compounds administered to these individuals for phosphate
control.
Recently a much more acute and dramatic form of aluminum
loading has been described in uremic patients. Bakir et al [13]
described four uremic patients, two not receiving dialysis, who
developed acute neurological illnesses and death within a
matter of weeks after being placed on combined therapy with
aluminum hydroxide and Shohl's solution (a buffer of citric acid
and sodium citrate). All of these patients had extremely high
plasma aluminum levels (380 to 1140 pg/liter, normal 7 3
pg/liter). In studying additional uremic patients, they found that
those patients receiving both aluminum hydroxide and Shohl's
solution had significantly higher plasma aluminum levels (160
32 pg/liter) than patients receiving either Shohl's solution (59
62 pg/liter) or aluminum hydroxide (73 32 pg/liter) alone.
Although these studies do not conclusively show that citrate
enhances aluminum absorption in uremic patients, they are
very suggestive.
We have recently evaluated a 67 year old, non-dialyzed male
with presumed hypertensive renal disease and a serum creati-
nine of 542 molIliter. The patient was placed on Shohl's
solution, 40 ml TID, in May 1985 and aluminum hydroxide (30
ml TID) was begun in February 1986. In March 1987, he was
evaluated for incapacitating leg pain. At this time his plasma
aluminum level was 551 pg/liter and bone histology showed
severe osteomalacia with a markedly increased osteoid area and
osteoid surface (Fig. 1). Double tetracycline labeling studies
revealed a corrected mineralization rate of 0.12 .tm/day,
whereas the control age and sex adjusted rated is 0.6 sm/day.
Also, the mineralization time, in days, was prolonged from a
control value of 24 days to 90.8 days. An aurin tricarboxylic
acid stain for aluminum revealed 100% aluminum staining of the
mineralization front (Fig. 1). Total bone aluminum content,
however, was only 33 mg/kg. To quantitate daily aluminum
absorption 24-hour urine collections were obtained and the
aluminum was determined. Daily urinary aluminum, while the
patient was on both Shohl's solution and A1OH, was 311
p.glday. When Shohl's solution was withheld urinary aluminum
excretion decreased to 200 JLg/day. With the resumption of
Shohl's solution, urinary aluminum rapidly increased to 365
pg/day (Fig. 2).
Further evidence supporting the enhancing effect of citrate on
the gastrointestinal absorption of Al is shown in Figure 3.
Following the withdrawal of Shohl's solution in May 1987 the
patient's plasma aluminum level decreased from 450 to 51
pg/liter even though he continued on the same dose of Al(OH)3.
This study clearly shows that the very high plasma and urinary
aluminum levels were directly a result of administering Shohi's
solution in combination with aluminum hydroxide. This patient
also demonstrates that besides inducing an acute neurological
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Fig. 1. A. Severe osteomalacia as shown by the von Kossa stain, x25, B. Aluminum staining using the aurin tricarboxylic acid stain, x40.
illness, the combination of citrate and aluminum hydroxide
therapy can cause the rapid onset of symptomatic osteomalacia.
It is of further interest that although there was extensive bone
aluminum present, as determined by the aluminum stain, total
bone aluminum was disproportionately low. This suggests that
the aluminum was largely present at the bone surface with little
present in the deeper areas. This supports the contention that
bone aluminum deposition was recent and of short duration.
The enhancement of aluminum absorption by citrate does not
seem to be restricted to sodium citrate, as virtually any citrate
compound can augment aluminum absorption [14—16]. Al-
though the combination of citrate and the uremic state may
possibly further enhance aluminum absorption; citrate has also
been shown to increase aluminum absorption in non-uremic
animals [14—16] and humans [17]. Two factors are responsible
for limiting the intestinal absorption of aluminum. First, the
gastrointestinal tract normally represents a major cellular bar-
rier to the absorption of non-essential metals. Second, most
naturally occurring aluminum compounds are highly insoluble.
The solubility of aluminum compounds is dependent upon the
pH of the aqueous solution [reviewed by Martin, 18]. Below pH
5 aluminum exists as A13 in the form of Al (H7O). As pH
increases there is successive deprotonation and in neutral
solutions aluminum exists as an insoluble Al(OH)3 precipitate
[18]. Citrate, however, enhances the solubility of Al3 by
favoring the formation of non-crystalline Al(OH)3 [18]. At a pH
between 2 and 5 a neutral soluble complex of citrate and
aluminum exists which could theoretically lead to enhanced
gastrointestinal absorption of aluminum, but direct documenta-
tion of this hypothesis is lacking.
In an attempt to directly evaluate the effect of pH and citrate
on the solubiity of aluminum salts in vitro studies were
undertaken [19]. Figure 4 shows the measured solubility of
aluminum from several aluminum salts at varying pHs. Sucral-
fate and aluminum hydroxide, while partially soluble at pH 3
are highly insoluble at pH 6 and 7. The solubility of aluminum
chloride and aluminum lactate is nearly complete at a pH of 3,
but again decreases as pH increases. Aluminum citrate remains
soluble throughout the pH range studied. In Figure 4B, the
effect of citrate on the solubility of aluminum in sucralfate and
aluminum chloride is shown. The addition of citric acid to
sucralfate (1:1) increased aluminum solubility from 13 to 46% at
pH 3. Increasing pH in the presence of citric acid had very little
effect on the solubility of aluminum from sucralfate. Citrate,
given as calcium citrate, had even a more marked effect on the
solubility of aluminum from aluminum chloride. Citrate, there-
fore, enhances the solubility of aluminum over the range of
physiologic pH seen in the gastrointestinal tract. Citrate could,
therefore, enhance aluminum absorption by increasing its sol-
ubility at the pH of the small intestinal fluid.
Documentation that aluminum movement is primarily via the
paracellular pathway comes from two different studies. Provan
and Yokel demonstrated, in in situ rat gut preparations, that
aluminum absorption occurred by an energy-independent
mechanism that could be limited by inhibitors known to block
the paracellular pathway [20]. Secondly, our laboratory has
recently developed in vivo and in vitro models to study the site
and cellular mechanism of citrate-enhanced aluminum absorp-
tion [21]. Following in vivo gavage of aluminum citrate in rats,
plasma aluminum concentrations peaked within 40 minutes, and
the absorption curve of aluminum mirrored that seen for
3H-glucose which was used as a marker of early proximal
intestinal absorption. In contrast, in vivo gavage of aluminum
chloride gave a very small broad response in plasma aluminum
with the maximal increase in plasma levels less than 2 percent
of that seen when the same amount of aluminum citrate was
administered (Fig. 5). In addition, using the 72-hour urinary
excretion of aluminum as an index of absorption, 50 times more
aluminum was excreted in the urine when aluminum citrate was
administered rather than aluminum chloride in the gavage
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Fig. 2. Effect of Shohl's solution on the 24-hour urinary excretion of
aluminum. Shohi's solution (40 ml tid) was given on days 1, 2, 7, and 8
and withheld on days 3 to 6 (horizontal bar). Twenty-four hour urinary
aluminum was determined on an aliquot using flameless atomic absorp-
tion.
Fig. 3. Effect of discontinuing Shohl's solution on plasma aluminum
levels, Shohl's solution was discontinued 5/87. The dose of aluminum
hydroxide was not altered. Plasma aluminum was determined using
flameless atomic absorption.
solution. Everted gut studies, using duodenal or jejunal seg-
ments, revealed marked enhancement of the transmural move-
ment of aluminum in the presence of citrate. In addition,
citrate-enhanced transmural movement of aluminum was tem-
perature independent. Since citrate is known to open epithelial
tight junctions [22] in cultured cells, we next questioned
whether citrate mediated its effect by enhancing paracellular
aluminum movement by transiently opening cellular tight junc-
tions between proximal intestinal cells. Using ruthenium red, a
low molecular weight surface membrane marker, in isolated
intestinal loop preparations aluminum citrate, but not aluminum
chloride nor normal saline, increased the presence of ruthenium
red deposits in intercellular spaces [211. This was especially
true around goblet cells. To further investigate the hypothesis
that citrate enhanced aluminum absorption by opening tight
junctions, Ussing chamber studies were conducted to deter-
mine the effect of aluminum citrate, aluminum chloride and
aluminum lactate on transmural resistances of proximal jejunal
pH
Fig. 4. The effect of pH and citrate on aluminum solubility from
different aluminum compounds. Each aluminum compound (110 mg/
liter) was mixed in distilled water and pH was adjusted using either HCI
or NaOH. Aluminum determinations were done on supernatants fol-
lowing centrifugation [19]. Symbols are: aluminum citrate (LI); alumi-
num hydroxide ('O); aluminum lactate (0); sucralfate (V); sucralfate +
citric acid, 1:1 molar ratio, (7); aluminum chloride (A) and aluminum
chloride + calcium citrate, 2.1/1 molar ratio of Ca2/Al3, (A).
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segments. Sodium citrate and EDTA were used as a positive
controls as they are known to open tight junctions and reduce
transmural electrical resistance in proximal jejunal segments.
Aluminum citrate, but not aluminum chloride nor aluminum
lactate, resulted in a prolonged decrease in transmural resis-
tance [21] consistent with the opening of tight junctions.
Since citrate is felt to open tight junctions by chelating
calcium it was next necessary to determine the calcium chelat-
ing ability of the citrate contained in aluminum citrate. This,
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Fig. S. Effect of administration of Al citrate or A/Cl3 on plasma
aluminum levels in rats. Either Al citrate (0.89 mmol/kg, N = 14) or
AId3 (1.3 mmol/kg, N = 3) was given to male rats via gavage and
plasma aluminum levels were determined at the times indicated. Values
represent the mean so. Symbols are: (•) Al citrate; (0) AICI3.
along with the calcium chelating ability of the anions in alumi-
num chloride and aluminum lactate was determined using a
calcium-selective ion electrode. Whereas aluminum citrate re-
sulted in the rapid and nearly complete (99.7 0.1%) chelation
of calcium, neither aluminum chloride nor aluminum lactate
resulted in significant calcium chelation [21]. Taken together
these data provide direct evidence that citrate enhances proxi-
mal gastrointestinal aluminum absorption by increasing alumi-
num solubility and by chelating calcium, which disrupts tightjunctions and allows for the markedly increased paracellular
flux of aluminum.
The very high aluminum blood levels seen in patients receiv-
ing both aluminum and citrate would help to explain the acute
neurotoxicity accompanying the usage of the combination of
these compounds. In the studies by Slanin et al [14, 16] brain
aluminum content increased three- and six-fold when aluminum
citrate and aluminum hydroxide with citric acid were fed
respectively, whereas no increase was seen when only Al(OH)3
was given. The two other conditions associated with acute
aluminum neurotoxicity, early during the course of deferoxam-
me therapy and dialysis with extremely contaminated dialysate,
are also accompanied by very high plasma aluminum levels. It
may be that in all these conditions either the aluminum levels
exceed transferrin's ability to bind aluminum or the aluminum is
already bound to a chelate such as deferoxamine or citrate
which permits it to readily pass the blood brain barrier causing
the neurotoxicity. In addition to causing neurotoxicity, the oral
ingestion of aluminum with citrate compounds can result in the
rapid production of aluminum-associated bone disease. There
are a number of other reports in the literature, especially in
children, where aluminum neurologic and skeletal toxicity have
occurred in individuals receiving aluminum hydroxide and
sodium citrate [23—26]. Also, in rats oral aluminum citrate
increases bone aluminum content 50-fold while Al(OH)3 only
caused a four-fold increase [14, 16].
In view of all the data available it is apparent that citrate
compounds should not be given with aluminum-containing
phosphate binding gels to uremic patients. In addition, because
of the propensity for uremic patients to retain aluminum, even
if not given oral aluminum compounds, it seems desirable not to
administer any citrate compounds because of their presumed
ability to further enhance aluminum absorption normally
present in the ingested water and food.
Although calcium citrate has recently been recommended as
an alternate phosphate binder to be used in uremic patients its
usage may be contraindicated. First, calcium citrate has the
ability to augment absorption of aluminum from food sources
[14, 15]. Second, it has also been the policy of most nephrolo-
gists to add aluminum hydroxide when an alternate phosphate
binder, such as calcium carbonate, is not totally effective in
controlling serum phosphate levels. Because of the potential of
a patient taking aluminum hydroxide or some other aluminum
containing medication it seems unwise to give a drug that has
the potential to cause acute aluminum intoxication. This is
especially true when other drugs are available which are equally
as effective, such as, calcium carbonate, but do not possess this
potential hazard. The use of Shohl's solution in the treatment of
uremic acidosis needs to be reevaluated. However, if the
aluminum-containing phosphate binder was administered with
meals and citrate containing solutions between meals, it is
possible that the citrate-enhanced aluminum absorption could
be avoided as citrate is rapidly absorbed and metabolized.
There are, however, no data to support this hypothesis. In
addition, recent data indicates that calcium acetate is a more
efficient phosphate binder than other calcium salts [26]. There-
fore, the need to use calcium citrate as a phosphate binding
agent must be questioned [27].
Until recently, the only exposure of the individuals with
normal renal function to citrate compounds has been as food
and drink additives. However, recently it has been suggested
that citrate compounds be used for the chronic treatment of
certain types of renal stone diseases and as a calcium supple-
ment used for the prevention of osteoporosis. Because of the
limited number of people with normal renal function who have
been on citrate compounds and their rather short duration of
exposure it is unclear what if any risks this poses. However,
since aluminum compounds, such as buffered aspirin, kaopec-
tate, aluminum hydroxide and sucralfate are readily available
and chronically used by a large number of individuals, it seems
possible that normal subjects receiving citrate may be at some
risk of developing aluminum overload and possible toxicity.
This idea is supported by the studies of Slanina et al [14—16],
which showed that the body burden of aluminum increased in
rats, with normal renal function, after consuming aluminum
citrate. In addition, since citrate can enhance the absorption of
other toxic elements such as lead [28, 29], it seems possible that
additional toxicities could result from routine environmental
exposures.
In conclusion, citrate compounds should not be administered
to uremic patients who are receiving compounds containing
aluminum. In fact, since toxicity can occur rapidly from the
concomitant usage of citrate and aluminum compounds, and
aluminum medications are so readily available and frequently
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used, a better policy might be the avoidance of citrate com-
pounds altogether in uremic patients. Sodium bicarbonate and
calcium carbonate or calcium acetate would appear to be
adequate substitutes for Shohi's solution and calcium citrate
respectively. Because of citrate's ability to induce aluminum
toxicity in uremic patients and its potential to produce toxicity
in normal subjects, the chronic administration of citrate con-
taining compounds should probably be avoided.
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